Table 1 lncRNA-H19 and therapy resistance of digestive system cancers
From: Role of long non-coding RNA H19 in therapy resistance of digestive system cancers
| Cancers | Cell samples | Expression in resistant cell | Biological mechanisms | Targets | Drugs | References |
|---|---|---|---|---|---|---|
| HCC | R-HepG2 | High | Regulating methylation of MDR1 promoter to induce P-gp expression; Knock-down of H19 inhibited the expression of MDR1/P-gp | H19-MDR1-P-gp | DOX | Tsang and Kwok (2007) |
| HepG2-GR | High | Up-regulating the expression of CD90, CD44 and CD133 | H19-CD90-CD44-CD133 | GEM | Yang and Yu (2019) | |
| Bel-7402, HepG2, Hep3b, QGY-7703, SMMC-7721 | No report | Targeting PSEN1 through the H19/mir-193a-3p axis | H19/miR-193a-3p/PSEN1 | Chemotherapy (DOX, paclitaxel, vinorelbine, 5-FU) and radiotherapy (single-dose X-ray) | Ma et al. (2018) | |
| HepG2/ADM | High | Mediating the EMT process through P-gp, ZEB1 and EC | H19-P-gp-ZEB1-EC-EMT | DOX and DDP | Li (2019) | |
| HepG2, Plc/Prf5, Huh7 | Low | Enhancing the cytotoxic effect of DOX or inhibiting cell proliferation | DOX and sorafenib | Schultheiss et al. (2017) | ||
| CD133 + HuH7, 42 patients tissues | High | Knock-down of H19 blocked the MAPK/ERK signaling pathway, decreasing the expression of MDR1 and GST-Π | H19-MAPK/ERK-MDR1-GST-Π | Ding et al. (2018) | ||
| 18 patients tissues, Huh7, Hep3B, SNU-449, SNU-387 | High | Knockdown of H19 sensitized HCC cells to sorafenib by downregulating miR-675 to suppress EMT | H19- miR-675- EMT | Sorafenib | Xu et al. (2020) | |
| CRC | HCT8, 110 patients tissues | High | Mediating the SIRT1 dependent autophagy pathway by combining with miR-194-5p | H19-miR-194–5p-SIRT1 | 5-FU | Wang et al. (2018a, b) |
| HCT116, SW480 | High | Exosomes derived from CAFs transferred H19 to colorectal cancer cells; LncH19 competed for the adsorption of miR-141 and activated the Wnt/β-catenin pathway | H19-miR-141-Wnt/β-catenin | Oxaliplatin | Ren et al. (2018) | |
| HT-29-R | High | Activation of the Wnt/β-catenin pathway | Wnt/β-catenin | Methotrexate | Wu et al. (2017) | |
| LoVo | High | Upregulating the MDR1, MRP1 and BCRP resistant proteins | H19-MDR1-MRP1-BCRP | 5-FU | Wang et al. (2018a, b) | |
| PDAC | PANC-1 | No report | No significant difference in the survival rate of cancer cells and expression of ABCG2, MRP1 and ABCC2 between the H19 overexpression group and low expression group | GEM, albumin paclitaxel and 5-FU | Sasaki et al. (2018) | |
| PANC-1 | High | Promoting metastasis of pancreatic cancer | 5-FU and abraxane | Yoshimura et al. (2018) | ||
| ESCA | KYSE150 | High | Inhibition of H19 up-regulated mir-22-3p expression and down-regulated WNT1 to inhibit the proliferation and migration of cancer cells | H19/miR-22-3p/WNT1 | Radiotherapy | Luo et al. (2019) |
| GC | 39 patients tissues, MKN7 | High | Inhibition of H19 reduced the survival rate of tumor cells and improved the sensitivity | H19/IGF2BP3 | DOX | Ishii et al. (2017) |
| SGC-7901/DDP | High | Decreasing the expression of FADD | H19/miR-675/FADD | DDP | Yan et al. (2017) | |
| CCA | QBC939 | High | Decreasing the cancer cell survival rate | GEM | Qiu (2017) |